

<b>F.9</b>	<b>Isoniazid IV injection 300 mg, 500 mg, 900 mg</b>
Does the application adequately address the issue of the public health need for the medicine?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not applicable  Comments: The application address the need for this medicine in general for TB for which oral isoniazid is indicated and includes potential scenarios where IV formulation would be necessary
Briefly summarize the role of the proposed medicine(s) relative to other therapeutic agents currently included in the Model List, or available in the market.	Oral isoniazid is already included in EML and the application is requesting for IV formulation among <b>severely ill patients and those who have absorption disorders</b>
Have all important studies and all relevant evidence been included in the application?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not applicable  If no, please provide brief comments on any relevant studies or evidence that have not been included:
Does the application provide adequate evidence of efficacy/effectiveness of the medicine for the proposed indication?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No <input type="checkbox"/> Not applicable  Briefly summarize the reported benefits (e.g. hard clinical versus surrogate outcomes) and comment, where possible on the actual magnitude and clinical relevance of benefit associated with use of the medicine(s).  Although the application includes target populations where it is beneficial, they don't provide evidence (lack of evidence) that IV has better efficacy compared to oral formulation. All references about malabsorption in HIV are reported in 1990's and no studies reported in the era of HAART.  Is there evidence of efficacy in diverse settings (e.g. low-resource settings) and/or populations (e.g. children, the elderly, pregnant patients)?
Does the application provide adequate evidence of the safety and adverse effects associated with the medicine?	<input type="checkbox"/> Yes <input checked="" type="checkbox"/> No <input type="checkbox"/> Not applicable  Comments: "Unfortunately there is no published information about specific side effects of isoniazid due to iv route of administration, it is assumed that all side effects may be similar to those that occur with prolonged infusions - inflammation and pain at the catheter insertion site, the risk of infection and thrombosis, but all these phenomena should be studied in a special study."

2021 Expert Committee on Selection and Use of Essential Medicines  
Application review

Are there any adverse effects of concern, or that may require special monitoring?	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not applicable Comments: Unknown
Briefly summarize your assessment of the overall benefit to risk ratio of the medicine (e.g. favourable, uncertain, etc.)	Uncertain- Patients still need to take oral TB meds. No evidence of superiority compared to oral drugs among targeted population
Briefly summarize your assessment of the overall quality of the evidence for the medicine(s) (e.g. high, moderate, low etc.)	low
Are there any special requirements for the safe, effective and appropriate use of the medicine(s)? (e.g. laboratory diagnostic and/or monitoring tests, specialized training for health providers, etc)	<input type="checkbox"/> Yes <input type="checkbox"/> No <input checked="" type="checkbox"/> Not applicable Comments:
Are you aware of any issues regarding the registration of the medicine by national regulatory authorities? (e.g. accelerated approval, lack of regulatory approval, off-label indication)	<input type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not applicable Comments: Only approved in few countries
Is the proposed medicine recommended for use in a current WHO Guideline approved by the Guidelines Review Committee? (refer to: <a href="https://www.who.int/publications/who-guidelines">https://www.who.int/publications/who-guidelines</a> )	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Not applicable Comments: Yes, only in specific situation- IV formulations should be reserved for cases of severe forms of disease, such as central nervous system (CNS) TB or TB sepsis. However, WHO working group recommends against including this medicine in EML due to potential overuse over oral drugs
Briefly summarize your assessment of any issues regarding access, cost and affordability of the medicine in different settings.	Tablets are cheaper than IV formulation however comparative cost-effectiveness studies are absent
Any additional comments	

2021 Expert Committee on Selection and Use of Essential Medicines  
Application review

Based on your assessment of the application, and any additional evidence / relevant information identified during the review process, briefly summarize your proposed recommendation to the Expert Committee, including the supporting rationale for your conclusions, and any doubts/concerns in relation to the listing proposal.	The recommendation is uncertain. There is limited role for IV isoniazid and despite using this IV, oral TB drugs (pyrazinamide) are still needed in intensive phase. All references about malabsorption in HIV are reported in 1990's and no studies reported in the era of HAART. Oral medications can still be given via temporary NG tube and in fixed dose combination pills.
References (if required)	